Scroll To Top

Nuke 'Em

Nuke 'Em


A new examination of Sustiva- and Viramune-based triple-drug regimens has shown that it isn't the choice between the two nonnucleoside analogs that predicts long-term viral control among treatment-naive HIVers but rather the accompanying nucleosides. The review, published in the April 6 issue of the Journal of Acquired Immune Deficiency Syndromes, shows that both Sustiva and Viramune are most successful when paired with two newer nukes than with such older combinations as Zerit plus Epivir or Videx plus Viread.

Advocate Channel - HuluOut / Advocate Magazine - Jonathan Groff and Wayne Brady

From our Sponsors

Most Popular

Latest Stories

HIV Plus Editors